Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries, Africa, and the Middle East. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Omega Diagnostics Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ODX is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ODX's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of UK stocks.
7 Day Return
GB Medical Equipment
1 Year Return
GB Medical Equipment
Return vs Industry: ODX exceeded the UK Medical Equipment industry which returned 0.6% over the past year.
Return vs Market: ODX exceeded the UK Market which returned 23.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Omega Diagnostics Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StThe Omega Diagnostics Group (LON:ODX) Share Price Has Soared 546%, Delighting Many Shareholders
1 month ago | Simply Wall StHow Much Of Omega Diagnostics Group PLC (LON:ODX) Do Institutions Own?
2 months ago | Simply Wall StHow Does Omega Diagnostics Group's (LON:ODX) CEO Salary Compare to Peers?
Is Omega Diagnostics Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ODX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ODX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ODX is unprofitable, so we can't compare its PE Ratio to the UK Medical Equipment industry average.
PE vs Market: ODX is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ODX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ODX is overvalued based on its PB Ratio (5.1x) compared to the GB Medical Equipment industry average (3.7x).
How is Omega Diagnostics Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Omega Diagnostics Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Omega Diagnostics Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ODX is currently unprofitable.
Growing Profit Margin: ODX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ODX is unprofitable, and losses have increased over the past 5 years at a rate of 77.7% per year.
Accelerating Growth: Unable to compare ODX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ODX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (13.8%).
Return on Equity
High ROE: ODX has a negative Return on Equity (-28.36%), as it is currently unprofitable.
How is Omega Diagnostics Group's financial position?
Financial Position Analysis
Short Term Liabilities: ODX's short term assets (£11.5M) exceed its short term liabilities (£1.5M).
Long Term Liabilities: ODX's short term assets (£11.5M) exceed its long term liabilities (£3.0M).
Debt to Equity History and Analysis
Debt Level: ODX is debt free.
Reducing Debt: ODX has no debt compared to 5 years ago when its debt to equity ratio was 0.7%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ODX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ODX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 22.9% each year.
What is Omega Diagnostics Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ODX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ODX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ODX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ODX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ODX's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Colin King (51 yo)
Mr. Colin King, MBA has been Chief Executive Officer at Omega Diagnostics Group PLC since December 14, 2017. Mr. King was Chief Operating Officer at Omega Diagnostics Group PLC since August 3, 2015 until D...
CEO Compensation Analysis
Compensation vs Market: Colin's total compensation ($USD283.82K) is below average for companies of similar size in the UK market ($USD566.51K).
Compensation vs Earnings: Colin's compensation has increased whilst the company is unprofitable.
Experienced Management: ODX's management team is seasoned and experienced (9.6 years average tenure).
Experienced Board: ODX's board of directors are considered experienced (6.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.4%.
Omega Diagnostics Group PLC's company bio, employee growth, exchange listings and data sources
- Name: Omega Diagnostics Group PLC
- Ticker: ODX
- Exchange: AIM
- Founded: 1987
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: UK£126.016m
- Shares outstanding: 182.63m
- Website: https://www.omegadiagnostics.com
Number of Employees
- Omega Diagnostics Group PLC
- Omega House
- Hillfoots Business Village
- FK12 5DQ
- United Kingdom
Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products in the United Kingdom, rest of Europe, North America, South/Central America, Indi...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/17 19:42|
|End of Day Share Price||2021/05/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.